Showing results (181-190 of 214) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|December 12, 2018
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterationsRichard J Lin, Caleb Ho, Patrick D Hilden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
British Journal of Haematology|October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Clinical Imaging|November 19, 2021
Multireader evaluation of radiologist performance for COVID-19 detection on emergency department chest radiographsJudy W Gichoya, Priyanshu Sinha, Melissa Davis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaParastoo B Dahi, Roni Tamari, Sean M Devlin, et al.
Leukemia & Lymphoma|February 8, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphomaSteven M Horwitz, Tatyana A Feldman, Jing Christine Ye, et al.
Haematologica|July 22, 2021
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphomaRichard J Lin, Colette N Owens, Esther Drill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphomaCraig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
Blood Advances|June 21, 2021
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphomaParastoo B Dahi, Jasme Lee, Sean M Devlin, et al.
Pageof 22